First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.

ESMO Open · 2021 · PMC7811117 · PMID 33450659

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

OS was numerically higher in the experimental arm (10.8 versus 9.7 months, HR 0.80, 95% CI 0.64-0.98; P = 0.0164) but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.